Results 81 to 90 of about 218 (97)
Some of the next articles are maybe not open access.

Toxicity by NSAIDs. Counteraction by Stable Gastric Pentadecapeptide BPC 157

Current Pharmaceutical Design, 2012
Stable gastric pentadecapeptide BPC 157 is an anti-ulcer peptidergic agent, proven in clinical trials to be both safe in inflammatory bowel disease (PL-10, PLD-116, PL 14736) and wound healing, stable in human gastric juice, with no toxicity being reported. Recently, we claim that BPC 157 may be used as an antidote against NSAIDs. We focused on BPC 157
Sikirić, Predrag   +18 more
openaire   +3 more sources

Stable gastric pentadecapeptide BPC 157 and bupivacaine

European Journal of Pharmacology, 2016
Bupivacaine toxicity following accidental overdose still lacks therapeutic solution. However, there are major arguments for testing BPC 157 against bupivacaine toxicity in vivo in rats, in particular, and then finally, in vitro. These are: the lack of any known BPC 157 toxicity, a lifesaving effect via the mitigation of arrhythmias in rats underwent ...
Živanović-Posilović, Gordana   +12 more
openaire   +3 more sources

Stable Gastric Pentadecapeptide BPC 157-NO-system Relation

Current Pharmaceutical Design, 2014
We reviewed stable gastric pentadecapeptide BPC 157-NO-system-relation, its close participation in Moncada's (maintained vascular integrity, platelets control) homeostatic healing response of NO-system to injury. Namely, BPC 157's particular healing effect also affects all events after vascular integrity loss (dependent on circumstances, it reduces ...
Sikirić, Predrag   +18 more
openaire   +4 more sources

Stable gastric pentadecapeptide BPC 157 heals rat colovesical fistula

European Journal of Pharmacology, 2016
To establish the effects of BPC 157 on the healing of rat colovesical fistulas, Wistar Albino male rats were randomly assigned to different groups. BPC 157, a stable gastric pentadecapeptide, has been used in clinical applications-specifically, in ulcerative colitis-and was successful in treating both external and internal fistulas.
Grgić, Tihomir   +10 more
openaire   +2 more sources

Stable gastric pentadecapeptide BPC 157 heals rectovaginal fistula in rats

Life Sciences, 2016
Rectovaginal fistula is a devastating condition providing more than 99% of patients for surgical treatment. We hypothesized that rectovaginal fistula may be healed by therapy with stable gastric pentadecapeptide BPC 157, in consistence with its initial clinical application and effect on external fistulas.BPC 157 (10μg/kg or 10ng/kg) was given perorally,
Barić, Marko   +10 more
openaire   +3 more sources

The stable gastric pentadecapeptide BPC 157, given locally, improves CO2 laser healing in mice [PDF]

open access: possibleBurns, 2005
The stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV; mol. wt. 1419), which is at present in phase II clinical trials for the treatment of inflammatory bowel disease, has been shown to counteract healing impairment by systemic corticosteroids in burned mice, both in vivo and in vitro, in the absence of carrier or protease inhibitor.
Sven Seiwerth, Predrag Sikiric
exaly   +4 more sources

Stable gastric pentadecapeptide BPC 157 in the therapy of the rats with bile duct ligation

European Journal of Pharmacology, 2019
Recently, stable gastric pentadecapeptide BPC 157 reversed the high MDA- and NO-tissue values to the healthy levels. Thereby, BPC 157 therapy cured rats with bile duct ligation (BDL) (sacrifice at 2, 4, 6, 8 week). BPC 157-medication (10 μg/kg, 10 ng/kg) was continuously in drinking water (0.16 μg/ml, 0.16 ng/ml, 12 ml/rat/day) since awakening from ...
Zenko Sever, Anita   +13 more
openaire   +4 more sources

Stable Gastric Pentadecapeptide BPC 157 as a Therapy of Severe Electrolyte Disturbances in Rats

Current Neuropharmacology
This review explores the therapeutic potential of the stable gastric pentadecapeptide BPC 157 in addressing electrolyte imbalances, specifically hyperkalemia, hypokalemia, hypermagnesemia, and hyperlithiemia.
Marija Medvidovic, Grubisic   +21 more
openaire   +2 more sources

Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157

Current pharmaceutical design, 2013
Stable gastric pentadecapeptide BPC 157 is an anti-ulcer peptidergic agent, proven in clinical trials to be both safe in inflammatory bowel disease (PL-10, PLD-116, PL 14736) and wound healing, stable in human gastric juice, with no toxicity being reported. Recently, we claim that BPC 157 may be used as an antidote against NSAIDs. We focused on BPC 157
Šebečić, Božidar   +15 more
openaire   +1 more source

Stable gastric pentadecapeptide BPC-157 heals transected muscle in rat.

Digestive diseases and sciences, 2003
Stable gastric pentadecapeptide BPC-157 heals transected muscle in rat.
Starešinić, Mario   +10 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy